You probably know that type 2 diabetes (T2D) is a prominent health concern, but do you know
How many of your patients with T2D have undiagnosed kidney disease?
In the United States, 32.6 million patients have T2D.1 Up to 40% of patients with T2D also have chronic kidney disease (CKD).2
Despite the high prevalence, ~90% of patients with diabetes and CKD are unaware of their kidney disease.3,*
Are your patients with CKD associated with T2D identified and treated appropriately?
What is the cardiovascular impact of CKD in patients with T2D?
What gaps in care exist for patients with CKD associated with T2D?
What factors are associated with CKD progression in patients with T2D?
To learn more about how CKD associated with T2D may be impacting your patient and member populations, what that means for the financial health of your organization, and what steps you can take to improve your performance on quality measures, Bayer invites you to review, download, and share the materials housed on this site.
Looking for educational resources about CKD associated with T2D?
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; UACR, urinary albumin-to-creatinine ratio.
*Estimates of diabetes may not delineate between type 1 and type 2 diabetes. According to the American Diabetes Association, type 2 diabetes accounts for 90%-95% of all diabetes cases. Therefore, statistics that describe diabetes may be more characteristic of type 2 diabetes.4
†As evidenced by a multicenter, observational study conducted in 466 primary care practices in the United States that assessed CKD prevalence within an adult, T2D population between 2011 and 2012. Investigators assessed the rate of appropriate CKD diagnosis, which was determined by conducting eGFR tests; HbA1c evaluations, a urine analysis to detect proteinuria, a urine measurement for UACR, 2 patient health-related quality-of-life questionnaires and a 15-month medical review were also performed.5
References: 1. Statistics about diabetes. American Diabetes Association. Accessed September 29, 2021. https://www.diabetes.org/resources/statistics/statistics-about-diabetes 2. Bailey RA, Wang Y, Zhu V, Rupnow MFT. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415. 3. United States Renal Data System. 2020 USRDS annual data report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020. Accessed September 29, 2021. https://adr.usrds.org/2020/chronic-kidney-disease/1-ckd-in-the-general-population 4. American Diabetes Association. Standards of medical care in diabetes—2022. Diabetes Care. 2022;45(suppl 1):S1-S264. 5. Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014;9(11):e110535. 6. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-308. 7. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns–NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016;4(1):e000154. 8. Murphy DP, Drawz PE, Foley RN. Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States. J Am Soc Nephrol. 2019;30(7):1314-1321. 9. National diabetes statistics report, 2020. Centers for Disease Control and Prevention. Accessed September 29, 2021. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf 10. Diabetic kidney disease. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed September 29, 2021. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease 11. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. 12. Mora-Fernández C, Domínguez-Pimentel V, Muros de Fuentes M, et al. Diabetic kidney disease: from physiology to therapeutics. J Physiol. 2014;592(18):3997-4012. 13. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertens. 2015;65(2):257-263. 14. Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
© 2022 Bayer. BAYER and the Bayer Cross are registered trademarks of Bayer. All rights reserved. Last updated 04/22
This site is intended for US-based population health managers only.
